A NEW METHOD TO EVALUATE THE CLINICAL EFFICACY OF PIRFENIDONE FOR PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS BY USING PERSONAL FORCED VITAL CAPACITY CHANGE

被引：0
|
作者：
Yamauchi, Hiroyoshi [1 ]
Bando, Masashi [1 ,2 ]
Ogura, Takashi [2 ,3 ]
Suda, Takafumi [2 ,4 ]
Taniguchi, Hiroyuki [2 ,5 ]
Mukae, Hiroshi [2 ,6 ]
Kishi, Kazuma [2 ,7 ]
Sugiyama, Yukihiko [1 ,2 ]
机构：
[1] Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi, Japan
[2] Minist Hlth Labour & Welf, Tokyo, Japan
[3] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
[4] Hamamatsu Univ Sch Med, Dept Resp Med, Shizuoka, Japan
[5] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Aichi, Japan
[6] Univ Occupat & Environm Hlth, Dept Resp Med, Fukuoka, Japan
[7] Toranomon Gen Hosp, Dept Resp Med, Tokyo, Japan
来源：
RESPIROLOGY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P-I-016
引用
收藏
页码：151 / 151
页数：1
相关论文
共 50 条
  • [31] Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
    Karishma Hosein
    Jamie Le
    Marco Mura
    Lung, 2017, 195 : 101 - 105
  • [32] Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
    Hosein, Karishma
    Le, Jamie
    Mura, Marco
    LUNG, 2017, 195 (01) : 101 - 105
  • [33] Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis A Randomized Clinical Trial
    Raghu, Ganesh
    van den Blink, Bernt
    Hamblin, Mark J.
    Brown, A. Whitney
    Golden, Jeffrey A.
    Ho, Lawrence A.
    Wijsenbeek, Marlies S.
    Vasakova, Martina
    Pesci, Alberto
    Antin-Ozerkis, Danielle E.
    Meyer, Keith C.
    Kreuter, Michael
    Santin-Janin, Hugues
    Mulder, Geert-Jan
    Bartholmai, Brian
    Gupta, Renu
    Richeldi, Luca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (22): : 2299 - 2307
  • [34] Variability in FEV1 in Comparison to Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis
    Ashraf, S.
    Wong, K. A.
    Agarwala, P.
    Salzman, S. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [35] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
    Santermans, Eva
    Ford, Paul
    Kreuter, Michael
    Verbruggen, Nadia
    Meyvisch, Paul
    Wuyts, Wim A.
    Brown, Kevin K.
    Lederer, David J.
    Byrne, Adam J.
    Molyneaux, Philip L.
    Sivananthan, Arunon
    Moor, Catharina C.
    Maher, Toby M.
    Wijsenbeek, Marlies
    ADVANCES IN THERAPY, 2019, 36 (11) : 3059 - 3070
  • [36] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
    Eva Santermans
    Paul Ford
    Michael Kreuter
    Nadia Verbruggen
    Paul Meyvisch
    Wim A. Wuyts
    Kevin K. Brown
    David J. Lederer
    Adam J. Byrne
    Philip L. Molyneaux
    Arunon Sivananthan
    Catharina C. Moor
    Toby M. Maher
    Marlies Wijsenbeek
    Advances in Therapy, 2019, 36 : 3059 - 3070
  • [37] Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?
    Rodriguez Moncalvo, Juan Jose
    Malet Ruiz, Jose
    Mastroianni, Marcelo
    Khoury, Marina
    Caro, Fabian
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [38] Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
    Noble, Paul W.
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    Glassberg, Marilyn K.
    Kardatzke, David
    King, Talmadge E., Jr.
    Lancaster, Lisa
    Sahn, Steven A.
    Szwarcberg, Javier
    Valeyre, Dominique
    du Bois, Roland M.
    LANCET, 2011, 377 (9779): : 1760 - 1769
  • [39] Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis
    Bando, Masashi
    RESPIRATORY INVESTIGATION, 2016, 54 (05) : 298 - 304
  • [40] Quartile Forced Vital Capacity Changes At 3, 6, 9, And 12 Months With Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis: A Pooled Phase Iii Analysis
    Bonella, F.
    Sussman, R.
    Ettinger, N.
    Zisman, D.
    Trzaskoma, B. L.
    Chou, W.
    Kardatzke, D.
    Costabel, U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
12345